PT3687523T - Tratamento de prurido colestático com seladelpar - Google Patents

Tratamento de prurido colestático com seladelpar

Info

Publication number
PT3687523T
PT3687523T PT188119549T PT18811954T PT3687523T PT 3687523 T PT3687523 T PT 3687523T PT 188119549 T PT188119549 T PT 188119549T PT 18811954 T PT18811954 T PT 18811954T PT 3687523 T PT3687523 T PT 3687523T
Authority
PT
Portugal
Prior art keywords
treatment
cholestatic pruritus
cholestatic
pruritus
Prior art date
Application number
PT188119549T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of PT3687523T publication Critical patent/PT3687523T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Ladders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PT188119549T 2017-09-26 2018-09-24 Tratamento de prurido colestático com seladelpar PT3687523T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26

Publications (1)

Publication Number Publication Date
PT3687523T true PT3687523T (pt) 2021-12-06

Family

ID=64564950

Family Applications (2)

Application Number Title Priority Date Filing Date
PT188119549T PT3687523T (pt) 2017-09-26 2018-09-24 Tratamento de prurido colestático com seladelpar
PT212018881T PT3973959T (pt) 2017-09-26 2018-09-24 Tratamento do prurido colestático com seladelpar

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT212018881T PT3973959T (pt) 2017-09-26 2018-09-24 Tratamento do prurido colestático com seladelpar

Country Status (26)

Country Link
US (2) US20190105291A1 (enExample)
EP (3) EP3687523B1 (enExample)
JP (1) JP7023371B2 (enExample)
KR (1) KR102376794B1 (enExample)
CN (1) CN111132675B (enExample)
AU (2) AU2018342323B2 (enExample)
BR (1) BR112020005074A2 (enExample)
CA (1) CA3076614C (enExample)
CY (1) CY1124894T1 (enExample)
DK (1) DK3973959T3 (enExample)
ES (2) ES3012120T3 (enExample)
FI (1) FI3973959T3 (enExample)
HR (2) HRP20250022T1 (enExample)
HU (2) HUE070033T2 (enExample)
IL (2) IL273569B (enExample)
LT (2) LT3973959T (enExample)
MX (1) MX392537B (enExample)
PL (2) PL3973959T3 (enExample)
PT (2) PT3687523T (enExample)
RS (1) RS62790B1 (enExample)
SG (1) SG11202002253SA (enExample)
SI (2) SI3687523T1 (enExample)
SM (1) SMT202200171T1 (enExample)
UA (1) UA125600C2 (enExample)
WO (1) WO2019067373A1 (enExample)
ZA (1) ZA202001646B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20210078515A (ko) 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치
KR20220140762A (ko) * 2020-02-10 2022-10-18 장피트 엘라피브라노에 의한 원발 담즙성 담관염의 치료
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
RS65546B1 (sr) 2021-02-01 2024-06-28 Cymabay Therapeutics Inc Tretman holangiopatija sa seladelparom
US20240252499A1 (en) 2023-01-29 2024-08-01 Cymabay Therapeutics, Inc. Treatment of uremic pruritus
KR20250139304A (ko) * 2023-01-29 2025-09-23 사이머베이 쎄라퓨틱스, 인코퍼레이티드 만성 소양증 피부병의 치료
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus
WO2026030533A1 (en) 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Seladelpar for use in treating liver disease
US20260207538A1 (en) 2024-12-20 2026-07-23 Gilead Sciences, Inc. Combinations for liver disease
CN121023009A (zh) * 2025-10-31 2025-11-28 浙江大学医学院附属妇产科医院(浙江省妇女医院、浙江省妇女保健院) 基于唾液样本的妊娠期肝内胆汁淤积症易感基因多重pcr—ngs筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
ES2701094T3 (es) * 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ

Also Published As

Publication number Publication date
EP3973959B1 (en) 2024-12-11
RU2020114644A (ru) 2021-10-27
US20190105291A1 (en) 2019-04-11
MX2020007273A (es) 2022-05-23
CA3076614C (en) 2023-02-07
IL288340B2 (en) 2023-05-01
WO2019067373A1 (en) 2019-04-04
SG11202002253SA (en) 2020-04-29
AU2021254641A1 (en) 2021-11-18
CY1124894T1 (el) 2023-01-05
ES2902349T3 (es) 2022-03-28
HUE070033T2 (hu) 2025-05-28
HRP20212010T1 (hr) 2022-04-01
LT3687523T (lt) 2022-03-25
EP4523744A3 (en) 2025-06-04
PL3687523T3 (pl) 2022-02-21
UA125600C2 (uk) 2022-04-27
CN111132675A (zh) 2020-05-08
PL3973959T3 (pl) 2025-03-24
DK3973959T3 (da) 2025-01-20
LT3973959T (lt) 2025-01-10
AU2021254641B2 (en) 2022-02-24
FI3973959T3 (fi) 2025-02-03
IL273569A (en) 2020-05-31
EP3973959A1 (en) 2022-03-30
AU2018342323A1 (en) 2020-04-16
SMT202200171T1 (it) 2022-05-12
US20210283078A1 (en) 2021-09-16
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
HUE057377T2 (hu) 2022-05-28
IL288340B1 (en) 2023-01-01
EP3973959B8 (en) 2025-01-15
ZA202001646B (en) 2021-08-25
SI3973959T1 (sl) 2025-03-31
AU2018342323B2 (en) 2021-09-23
KR20200058458A (ko) 2020-05-27
PT3973959T (pt) 2025-01-24
BR112020005074A2 (pt) 2020-09-15
SI3687523T1 (sl) 2022-05-31
MX392537B (es) 2025-03-04
EP3687523B1 (en) 2021-11-03
IL288340A (en) 2022-01-01
EP3687523A1 (en) 2020-08-05
ES3012120T3 (en) 2025-04-08
NZ762976A (en) 2021-11-26
IL273569B (en) 2021-12-01
CA3076614A1 (en) 2019-04-04
JP2020535225A (ja) 2020-12-03
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (enExample) 2022-02-14
JP7023371B2 (ja) 2022-02-21
CN111132675B (zh) 2023-04-25
RS62790B1 (sr) 2022-02-28

Similar Documents

Publication Publication Date Title
ZA202001646B (en) Treatment of cholestatic pruritus
ZA202006746B (en) Methods of treatment
IL259110A (en) Treatment of osteoarthritis
ZA201807084B (en) Methods of treatment of cholestatic diseases
IL253802A0 (en) A preparation for the treatment of osteoporosis
IL250677A0 (en) Cancer treatment using anti-nkg2a agents
IL285003A (en) Treatment of episode disorders
SG11201900257UA (en) Device for hyperthermia treatment of pruritus
SG10202001285XA (en) Chloride salt of tat-nr2b9c
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
LT3661510T (lt) Elgesio pakitimų gydymo būdai
PL3269340T3 (pl) Urządzenie do hipertermicznego leczenia świądu
GB201416832D0 (en) Methods of treatment
IL255498A (en) Treatment of pruritus
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
IL273543A (en) A new treatment for SMA
GB201514729D0 (en) Treatment of haemorrhoids
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
PT3661510T (pt) Métodos de tratamento de alterações do comportamento
GB201721386D0 (en) Chrondogy of time-wave
GB201612485D0 (en) Method of treatment of obesity
GB201604377D0 (en) Method of treatment of obesity
GB201417465D0 (en) Treatment of cancers